

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 March 2003 (13.03.2003)

PCT

(10) International Publication Number
WO 03/020978 A1

(51) International Patent Classification⁷: **C12Q 1/68**

(74) Agent: **LEE, Young-Pil**; The Cheonghwa Building,
1571-18, Seocho-dong, Seocho-gu, 137-874 Seoul (KR).

(21) International Application Number: **PCT/KR02/01645**

(22) International Filing Date: **30 August 2002 (30.08.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
2001/53687 1 September 2001 (01.09.2001) **KR**
2002/48128 14 August 2002 (14.08.2002) **KR**

(71) Applicant: **SAMSUNG ELECTRONICS CO., LTD.**
[KR/KR]; 416 Maetan-dong, Paldal-gu, Suwon-city,
442-373 Kyungki-do (KR).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN,
YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **METHOD FOR MANUFACTURING HYDROGEL BIOCHIP BY USING STAR-LIKE POLYETHYLENE GLYCOL DERIVATIVE HAVING EPOXY GROUP**



(57) Abstract: A method for manufacturing a biochip and a biochip manufactured by the method are provided. In the biochip manufacturing method, a star-like polyethylene glycol derivative having an epoxy group at its terminal is reacted with a low molecular weight hydrophilic polymer to form a matrix, and a probe is covalently bound to the matrix and immobilized on a solid substrate. The biochip has a 3-dimensional structure where it spatially protrudes from its surface and improved chip sensitivity. In addition, the biochip can be conveniently and efficiently manufactured using an aqueous solution at low costs.

WO 03/020978 A1

BEST AVAILABLE COPY

**METHOD FOR MANUFACTURING HYDROGEL BIOCHIP
BY USING STAR-LIKE POLYETHYLENE GLYCOL DERIVATIVE
HAVING EPOXY GROUP**

5 Technical Field

The present invention relates to a method for manufacturing a biochip, and more particularly, to a method for manufacturing a biochip by using a gel matrix.

Background Art

10 The completion of the human genome project has greatly increased the need for an efficient method for providing a large quantity of genetic information necessary for genetic disease diagnosis, treatment, and prevention. Despite the development of DNA polymerase chain reaction(PCR) and its automization, the Sanger's method for nucleotide sequencing is still burdensome and delicate to handle, and needs lots of time, effort, and cost. Thus, there have been many
15 attempts to find a new nucleotide sequencing system capable of analyzing a large number of genes.

 A DNA chip refers to a microarray of less than 1 square inch, which is formed by immobilizing oligonucleotide probes, each probe including a few to hundreds of nucleotides, at hundreds to hundreds of thousands of appropriate
20 positions on a solid surface made of silicon, surface-modified glass, polypropylene, or activated polyacrylamide. As a target DNA fragment is bound to the DNA chip, the target DNA fragment complementarily hybridizes to the oligonucleotide probes immobilized on the DNA chip. The hybridization is optically or radiochemically observed and analyzed to identify the nucleotide
25 sequence of the target DNA.

 Use of the DNA chip reduces the size of a DNA assay system and enables genetic assay with a trace of a sample. In addition, multiple sequences of a target DNA can be simultaneously assayed, thereby conveniently and rapidly providing the genetic information of the target DNA at low costs. The DNA chip
30 can assay a large amount of genetic information and the relevancy of the genes within a short period of time. Accordingly, the DNA chip is expected to have wide

applications, for example, to genetic disorder and cancer diagnosis, mutant and pathogen detection, gene expression assay, drug discovery, etc. In addition, the DNA chip can be used as a microorganism or pollutant detector to find out antidotal genes and further to produce antidotes on a large scale based on genetic recombination technologies. The DNA chip can lead to great improvements in most biological industries, including the production of medicinal crops or low-fat meat.

DNA chips are classified into an oligo-chip and a cDNA chip according to the type of probes immobilized thereon. According to the manufacturing method, DNA chips are classified into a lithography chip, a pin-type spotting chip, an ink-jet type spotting chip, and an electronic addressing DNA chip that electronically integrates DNA into a substrate.

The first generation DNA chip, a 2-dimensional (2D) chip in which oligonucleotides are attached to a substrate as a monolayer, causes a considerable error when the degree of hybridization is relatively compared, due to spot-to-spot variation of the probes attached to the substrate, and has low sensitivity, and thus needs an expensive confocal fluorescence microscope to detect the hybridized DNA. In addition, the surface of the solid substrate is treated with a mixture of an organic solvent and an aqueous solution to induce chemical reactions.

U.S. Patent No. 5,744,305 discloses an example of the first generation DNA chip manufactured by photolithography using a photolabile protecting group. In the first generation DNA chip, various polymers such as peptides and oligonucleotides are arrayed on the substrate.

To address the drawbacks of the first generation DNA chip, the following second generation DNA chip was developed. U.S. Patent Nos. 5,736,257 and 5,847,019 disclose methods for manufacturing biochips, in which a hydroxyl (OH) group on a substrate is treated with silane to form a molecular layer of a vinyl group on the substrate, and a network layer is formed on the molecular layer through polymerization of acrylamide and activated and patterned using light to bind the network layer to a biomaterial. In these methods, due to a 3-D gel

network of the polyacrylamide formed on the molecular layer of the vinyl group, a quantitative variation of probes immobilized thereon is reduced, and chip sensitivity is improved. However, disadvantageously, the cost is high and a long assay period of time is required.

5 U.S. Patent Nos. 5,552,270, 5,741,700, and 5,770,721 disclose DNA sequence assay methods using a second generation DNA chip including an oligonucleotide array matrix and a solid substrate. The matrix is bound to the solid substrate via a gel layer in a pattern of square dots spaced a constant distance from one another. In the manufacture of the DNA chip, a
10 polyacrylamide gel is applied between two glass slides spaced about 30 μm apart. One glass slide having the size of $100 \times 100 \times 30 \mu\text{m}^3$ is removed, and the remaining glass slide coated with the gel is dried and formed into a dot pattern by partially removing the gel through a mechanical tool or laser. The amide group of the gel layer is chemically transformed into reactive hydrazide form, and DNA
15 probes having N-methyluridine at 5'-terminal are transformed into dialdehyde. The oligonucleotide probe is immobilized on the substrate in three dimensions by reacting the probe with the reactive gel.

The DNA chip is manufactured through multiple processes over a longer period of time of from 1 to 2 days, wherein each of the processes is followed by a
20 thorough wash process. Accordingly, the assay yield is susceptible to reaction conditions, and irregular adsorption of the target DNA to the gel surface increases background noise.

WO 00/65097 and WO 00/2899 disclose 3-D DNA chips using a hydrogel having an isocyanate (NCO) group. The hydrogel is a hydrophilic network
25 polymer which is glassy in a dehydrated state and swells to form a gel in the presence of water. According to the disclosures, the isocyanate group is known to involve in covalent bonding between the hydrogel and probes as well as in polymerization of the hydrogel itself. A hydrogel having the isocyanate group, for example, polyethyleneoxide having an isocyanate group or a copolymer of
30 polyethyleneoxide having an isocyanate group and polypropyleneoxide, and probes having an amine group at the 5'-terminal are mixed in an aqueous solution,

and the probes are immobilized on the gel in three dimensions and reacted with an amine group on the glass surface to attach the probes on the substrate.

The isocyanate group is hydrolyzed too rapidly to control. To prevent the hydrolysis of the isocyanate group there is a need to manufacture a DNA chip at low temperature. As the isocyanate groups that neither covalently bind to the probes nor are involved in gel polymerization are hydrolyzed, the polymerization is accelerated to increase viscosity and to solidify a spotting pin. Also, generation of carbon dioxide makes spotting size control difficult.

Disclosure of the Invention

It is an object of the present invention to provide an easy-to-manufacture hydrogel biochip having an improved sensitivity.

It is another object of the present invention to provide a method for manufacturing a biochip having an improved sensitivity.

The present invention provides a method for manufacturing a hydrogel biochip, comprising: mixing a star-like polyethylene glycol derivative having an epoxy group at its terminal, a hydrophilic polymeric cross-linking agent and a probe in a aqueous solution to form a mixture solution; and applying the mixture solution on a substrate to form a hydrogel such that the probe is immobilized to the substrate.

The method for manufacturing the hydrogel biochip according to the present invention may comprise forming a matrix of a star-like polyethylene glycol derivative having an epoxy group at its terminal and a hydrophilic polymeric cross-linking agent and reacting the matrix with a probe to form a matrix-probe conjugate.

The hydrogel biochip manufacturing method according to the present invention will be described in detail below.

Initially, a star-like polyethylene glycol is reacted with excess epichlorohydrine and sodium hydroxide to have an epoxy group to its terminal. Next, the matrix is formed by using a low molecular weight hydrophilic polymer,

and preferably, having a hydrophilic hydroxy group, amino group, or thiol group, and having an average molecular weight of about 60-100,000 as a cross-linking agent. A probe having a nucleophilic group at its terminal is covalently bound to the matrix to form the matrix-probe conjugate. The formation of the matrix and the formation of the matrix-probe conjugate are sequentially or simultaneously performed. The term "probe" used throughout the specification means all substances specifically bound to a target substance and useful to measure the properties of the target substance through analysis of the binding between the probe and the target substance. Preferably, the probe includes nucleic acids, such as deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and peptide nucleic acid (PNA), a protein, or an oligopeptide. The low molecular weight hydrophilic polymer used in the present invention includes polyethylene glycol having, for example, an average molecular weight of 60-100,000, polyethylenamine, polypropyleneoxide and polyol. The term "star-like polyethylene glycol" used throughout the specification means a PEG derivative having branches oriented in 3 or more directions, thereby having a star-like form. Thus, the star-like PEG derivatives of the present invention can be cross-linked by a cross-linking agent and form a 3-dimensional polymer matrix.

According to the present invention, the matrix-probe conjugate is immobilized on a solid substrate, and preferably, whose surface is treated to expose an amide group, by microspotting to form the hydrogel biochip according to the present invention. Suitable materials for the solid substrate include glass, quartz, silicon, plastic, polypropylene, polycarbonate, and activated acrylamide, etc.

The method for manufacturing the hydrogel biochip according to the present invention includes preparing a mixture solution of a star-like polyethylene glycol having an epoxy group at its terminal, a hydrophilic cross-linking agent, and a probe, and immobilizing the mixture solution on substrate.

The immobilization is performed, for example, at a temperature of about 40-70°C and a humidity of about 60-30%, and preferably, at 40°C and 60%, 60°C

and 40%, or 70°C and 30%. The spot pattern formed on the substrate as a result of the immobilization varies depending on the type of the cross-linking agent and reaction conditions such as mixing ratio, temperature, and humidity. In this particular embodiment of the present invention, the same polyethylene derivative, hydrophilic polymeric cross-linking agent, probe, and substrate as described above are applied.

The present invention provides a hydrogel biochip manufactured by the above-described hydrogel biochip manufacturing method. The hydrogel biochip according to the present invention comprises a solid substrate, a matrix covalently bound to the solid substrate as a reaction product between a star-like polyethylene glycol having an epoxy group at its terminal and a hydrophilic polymeric cross-linking agent, and probes covalently bound to the matrix.

The present invention also provides an assay method for detecting a binding between a probe and a target sample, comprising applying the target sample including a target substance to be bound to the probe to the hydrogel biochip manufactured by the method according to the present invention and detecting the target substance specifically bound to the probe. It is preferable to label the probe with a signaling substance, such as a fluorescent dye for easy detection of the target substance. The binding between a probe and a target substance can be detected by a variety of methods, for example, a fluorescent detection method, an electrochemical detection method, a mass detection method, a charge detection method, or an optical detection method, which are currently in wide use and are classified according to the type of the signaling substance labeled to the target substance.

Brief Description of the Drawings

FIG. 1 is a photograph showing the result of hybridization when a full length of the wild type gene of hepatocyte nuclear factor-1 α (HNF-1 α) is used as a target nucleotide;

FIG. 2 is a photograph showing the result of hybridization when a heterozygote mutant obtained by an insertion of nucleotide A immediately after

the 5613th nucleotide of exon 9 of the HNF-1 α gene is used as a target nucleotide; and

FIG. 3 is a photograph showing the result of fluorescent scanning performed after hybridization of a target nucleotide to a biochip manufactured in
5 Example 6 according to the present invention.

Best mode for carrying out the Invention

The present invention will be described in greater detail with reference to the following examples. The following examples are for illustrative purposes and
10 are not intended to limit the scope of the invention.

Example 1: Synthesis of star-like Polyethylene Glycol having Epoxy Group

7.5 mL of epichlorohydrine and 0.32 g of tetrabutylammonium bromide
15 were added to 2 mL of NaOH solution (50% by weight) and stirred, and 1 g of pentaerythritol ethoxylate was slowly added to the mixture and stirred at room temperature for 18 hours. The completion of the reaction was identified by thin layer chromatography. When the reaction was not completed, the mixture was further stirred for 1 hour at 60°C. Next, the reaction product was diluted with an
20 addition of 30 mL of water and extracted three times with 40 mL of methylene chloride. An organic solvent layer was washed three times with 40 mL of saturated NaHCO₃, and anhydrous MgSO₄ was added, and the solvent was removed at a low pressure. Next, the resultant product was dried in a vacuum for 2 days to remove the epichlorohydrine residue. The resultant star-like
25 polyethylene glycol (PEG) derivative having an epoxy group was identified by H-NMR and titration of the epoxy group using 0.1 N HBr/glacial acetic acid.

Example 2: Synthesis of Diamine Cross-linking Agent

5 g (9.2 mmol) of penta(ethylene glycol)di-tosylate was dissolved in 40 mL
30 of DMF, and 4.2 g of (64.1 mmol) NaN₃ and 0.5 mL of pyridine were sequentially added to the solution and stirred at 140°C for 18 hours. After removing the

solvent at a low pressure, the resultant product was stirred with an addition of 200 mL of water and extracted with 100 mL of methylene chloride. An organic solvent layer was washed three times with 100 mL of brine, and anhydrous MgSO_4 was added, and the solvent was removed at a low pressure. Next, the resultant product was subjected to flash column chromatography (EA:nHex = 1:2) to isolate a diazide intermediate product. The intermediate product was dissolved in 30 mL of methanol, and 10% Pd-C (0.1 equivalent) was added, followed by a reduction reaction for 18 hours using hydrogen gas. A catalyst was removed using a Celite pad, and the pad was washed with ethanol. The filtrate and the ethanol used to wash the pad were mixed, and the solvent was removed at a low pressure to obtain a diamine cross-linking agent.

Example 3: Preparation of Gel Matrix Solution using Cross-linking Agent

(1) Preparation of Gel matrix solution using diamine cross-linking agent
100 mg of the star-like PEG derivative having the epoxy group prepared in Example 1 was stirred with an addition of 4 mL water. 5.8 mg of the diamine cross-linking agent synthesized in Example 2 was added to the mixture and stirred at room temperature for 18 hours and stored in a liquid state at 4°C.

(2) Preparation of Gel Matrix Solution using PEG as a cross-linking agent
PEG having a molecular weight of 200, 400, 600, and 1,500 were separately dissolved in an aqueous solution of 2 N NaOH and stirred in an ice bath to obtain different PEG cross-linking agent solutions.

Next, a portion of the star-like PEG derivative having the epoxy group prepared in Example 1 was dissolved in a carbonate buffer solution (0.1 M, pH 9.1). The prepared PEG cross-linking solution was slowly added into the solution and stirred at room temperature for 3 hours. After the completion of the reaction, the reaction product was extracted with methylene chloride, and the solvent was removed at a low pressure and stored at 4°C.

For comparison, when a gel matrix solution was prepared using a PEG

cross-linking solution having a molecular weight of 100,000, a solid reaction product was obtained. As a result of the gel permeation chromatography, the solid product was identified as a dimer having 5-6 epoxy groups, rather than the matrix material. Accordingly, it is evident that PEG having a molecular weight of less than 100,000 can be used as the cross-linking agent in the present invention.

Example 4: Manufacture of Biochip by Spotting Gel Matrix-DNA conjugate solution

To the gel matrix solution prepared in Example 3, oligonucleotide probes including the star-like PEG having the epoxy group, the cross-linking agent, and oligonucleotides in an equivalent ratio of 4:1:4 were added, stirred at 37°C, and left for 14 hours to obtain a spotting solution of a matrix-DNA conjugate.

The spotting solution was applied by spotting to a glass substrate whose surface had been treated to expose an amine group and left in a wet chamber at 37°C for 4 hours. To prevent the target nucleic acid from adhering to an unnecessary portion on the glass surface, further reaction is performed such that amine groups at non-spotting positions on the glass substrate were negatively charged, which is an essential step for controlling background noise, and the resultant biochip was stored in a dryer.

Example 5: Chip Test

In the chip performance test, a full length of the wild type gene of hepatocyte nuclear factor-1 α (HNF-1 α) and a heterozygote mutant obtained by an insertion of nucleotide A immediately after (toward 3'-terminal) the 5613th nucleotide of exon 9 of the HNF-1 α amplified through multiplex polymerase chain reaction (PCR) were used as a target nucleotide to be hybridized to the probe. In the PCR of the target nucleotide, Cy3-dUTP was added to fluorescently label the target nucleotide.

The following oligonucleotides (SEQ ID Nos. 1 through 34) were used as probes.

For hybridization of the target nucleotide to the probes, 20 nM target nucleotide solution in 0.1% 6SSPET (Saline Sodium Phosphate EDTA buffer containing 0.1% Triton X-100) and a matrix-DNA conjugate were immobilized on the chip and reacted at 37°C for 16 hours. The chip was washed at room temperature with 0.05% 6SSPET and 0.05% 3SSPET in sequence for 5 minutes each, air-dried at room temperature for 5 minutes, and scanned by a scanner (Exon Co., GenePix 4000B).

SEQ ID No. 1: tgaacttTggacttc - a probe complementary to HNF-1 α gene promoter region, wherein T in the middle of the probe sequence is paired with the 432nd base of the wild type promoter, and its side probe sequence perfectly matches the side sequence of the 432nd base.

SEQ ID No. 2: tgaacttGggacttc - a probe complementary to a target nucleotide having a point mutation (A→C) at the 432nd base of the wild type promoter.

SEQ ID No. 3: gttttggGggggcag - a probe complementary to HNF-1 α gene promoter region, wherein G in the middle of the probe sequence is paired with the 592nd base of the wild type promoter, and its side probe sequence perfectly matches the side sequence of the 592nd base.

SEQ ID No. 4: gttttggCggggcag - a probe complementary to a target nucleotide having a point mutation (C→G) at the 592nd base of the wild type promoter.

SEQ ID No. 5: tgcagctGgctcagt - a probe complementary to HNF-1 α gene exon 1 region, wherein G in the middle of the probe sequence is paired with the 733rd base of the wild type exon 1, and its side probe sequence perfectly matches the side sequence of the 733rd base of exon 1.

SEQ ID No. 6: tgcagctAgctcagt - a probe complementary to a target nucleotide having a point mutation (C→T) at the 733rd base of the wild type exon 1.

5

SEQ ID No. 7: gcactggGtgagccg - a probe complementary to HNF-1 α gene exon 1 region, wherein G in the middle of the probe sequence is paired with the 806th base of the wild type exon 1, and its side probe sequence perfectly matches the side sequence of the 806th base of exon 1.

10

SEQ ID No. 8: gcactggAtgagccg - a probe complementary to a target nucleotide having a point mutation (C→T) at the 806th base of the wild type exon 1.

15

SEQ ID No. 9: caaggggGagtcctg - a probe complementary to HNF-1 α gene exon 1 region, wherein G in the middle of the probe sequence is paired with the 856th base of the wild type exon 1, and its side probe sequence perfectly matches the side sequence of the 856th base of exon 1.

20

SEQ ID No. 10: caaggggAagtcctg - a probe complementary to a target nucleotide having a point mutation (C→T) at the 856th base of the wild type exon 1.

25

SEQ ID No. 11: cggtcgaGgggagct - a probe complementary to HNF-1 α gene exon 1 region, wherein G in the middle of the probe sequence is paired with the 875th base of the wild type exon 1, and its side probe sequence perfectly matches the side sequence of the 875th base of exon 1.

30

SEQ ID No. 12: ggcggtcGagctggc - a probe complementary to a target nucleotide having a deletion mutation of 5 bases from the 875th to 879th bases of

the wild type exon 1.

SEQ ID No. 13: accatctTcgccaca - a probe complementary to HNF-1 α gene exon 2 region, wherein T in the middle of the probe sequence is paired with the 1778th base of the wild type exon 2, and its side probe sequence perfectly matches the side sequence of the 1778th base of exon 2.

SEQ ID No. 14: accatctCcgccaca - a probe complementary to a target nucleotide having a point mutation (A→G) at the 1778th base of the wild type exon 2.

SEQ ID No. 15: cacaacaTcccacag - a probe complementary to HNF-1 α gene exon 2 region, wherein T in the middle of the probe sequence is paired with the 1812th base of the wild type exon 2, and its side probe sequence perfectly matches the side sequence of the 1812th base of exon 2.

SEQ ID No. 16: cacaacaAcccacag - a probe complementary to a target nucleotide having a point mutation (A→T) at the 1812th base of the wild type exon 2.

SEQ ID No. 17: gcgggccGccctgta - a probe complementary to HNF-1 α gene exon 2 region, wherein G in the middle of the probe sequence is paired with the 1910th base of the wild type exon 2, and its side probe sequence perfectly matches the side sequence of the 1910th base of exon 2.

SEQ ID No. 18: gcgggccAccctgta - a probe complementary to a target nucleotide having a point mutation (C→T) at the 1910th base of the wild type exon 2.

SEQ ID No. 19: acctctcGctgcttg - a probe complementary to HNF-1 α

gene exon 2 region, wherein G in the middle of the probe sequence is paired with the 1940th base of the wild type exon 2, and its side probe sequence perfectly matches the side sequence of the 1940th base of exon 2.

5 SEQ ID No. 20: acctctcActgcttg - a probe complementary to a target nucleotide having a point mutation (C→T) at the 1940th base of the wild type exon 2.

10 SEQ ID No. 21: aaggggcGgaggaac - a probe complementary to HNF-1 α gene exon 3 region, wherein G in the middle of the probe sequence is paired with the 2659th base of the wild type exon 3, and its side probe sequence perfectly matches the side sequence of the 2659th base of exon 3.

15 SEQ ID No. 22: aaggggcAgaggaac - a probe complementary to a target nucleotide having a point mutation (C→T) at the 2659th base of the wild type exon 3.

20 SEQ ID No. 23: gaggaacCgtttcaa - a probe complementary to HNF-1 α gene exon 3 region, wherein C in the middle of the probe sequence is paired with the 2667th base of the wild type exon 3, and its side probe sequence perfectly matches the side sequence of the 2667th base of exon 3.

25 SEQ ID No. 24: gaggaacTgtttcaa - a probe complementary to a target nucleotide having a point mutation (G→A) at the 2667th base of the wild type exon 3.

30 SEQ ID No. 25: cacctccGtgacgag - a probe complementary to HNF-1 α gene exon 4 region, wherein G in the middle of the probe sequence is paired with the 3297th base of the wild type exon 4, and its side probe sequence perfectly matches the side sequence of the 3297th base of exon 4.

SEQ ID No. 26: cacctccAtgacgag - a probe complementary to a target nucleotide having a point mutation (C→T) at the 3297th base of the wild type exon 4.

5

SEQ ID No. 27: tagacacGcacctcc - a probe complementary to HNF-1 α gene exon 4 region, wherein G in the middle of the probe sequence is paired with the 3305th base of the wild type exon 4, and its side probe sequence perfectly matches the side sequence of the 3305th base of exon 4.

10

SEQ ID No. 28: tagacacAcacctcc - a probe complementary to a target nucleotide having a point mutation (C→T) at the 3305th base of the wild type exon 4.

15

SEQ ID No. 29: caaccggCgcaaaga - a probe complementary to HNF-1 α gene exon 4 region, wherein C in the middle of the probe sequence is paired with the 3332th base of the wild type exon 4, and its side probe sequence perfectly matches the side sequence of the 3332th base of exon 4.

20

SEQ ID No. 30: caaccggTgcaaaga - a probe complementary to a target nucleotide having a point mutation (G→A) at the 3332th base of the wild type exon 4.

25

SEQ ID No. 31: cctgagaTgccggcg - a probe complementary to HNF-1 α gene exon 9 region, wherein T in the middle of the probe sequence is paired with the 5613th base of the wild type exon 9, and its side probe sequence perfectly matches the side sequence of the 5613th base of exon 9.

30

SEQ ID No. 32: cctgagaTgccggc - a probe complementary to a target

nucleotide having an insertion mutation of base A immediately after the 5613th base of the wild type exon 9.

5 SEQ ID No. 33: tggcgctGagccggt - a probe complementary to HNF-1 α gene exon 9 region, wherein G in the middle of the probe sequence is paired with the 5688th base of the wild type exon 9, and its side probe sequence perfectly matches the side sequence of the 5688th base of exon 9.

10 SEQ ID No. 34: tggcgctGagagccg - a probe complementary to a target nucleotide having an insertion mutation of bases T and C immediately after the 5688th base of the wild type exon 9.

The result of scanning after the hybridization reaction between the probes and the target nucleotide is shown in FIGS. 1 and 2. FIG. 1 is for the full length of the wild type gene of HNF-1 α used as the target nucleotide. FIG 2 is for the
15 heterozygote mutant used as the target nucleotide, which was obtained by an insertion of nucleotide A immediately after the 5613th nucleotide of exon 9 region of the HNF-1 α gene.

In FIGS. 1 and 2, 6 spots for each identical probe were spotted on the chip, from the left to the right in the uppermost line, probes of SEQ ID Nos. 1, 2, 3, and
20 4 were immobilized as spots. In the next line, probes of SEQ ID Nos. 5, 6, 7, and 8 were immobilized in the same manner. The remaining probes up to SEQ ID No. 34 were spotted on the chip in the same manner. Here, the spot size was $170 \pm 5 \mu\text{m}$, and the spot interval was adjusted to be $375 \mu\text{m}$.

A spot-to-spot variation in the identical probe group was 8%, and a
25 chip-to-chip variation was 10.6%, when measured as a coefficient of variation (CV). Comparing to conventional 2D chips having a 25-30% coefficient of spot-to-spot variation, the 3D immobilization technique applied in the present invention is proved to be effective in reducing an error between probes. CV is expressed as a percentage of standard deviation to mean value.

30 As shown in FIG. 1, the immobilized spots of the wild type probes (i.e., SEQ ID Nos. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, and 33)

showed a strong fluorescent intensity, compared with the immobilized spots of the mutant probes (i.e., SEQ ID Nos. 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 34). Accordingly, the full length of the wild type gene of HNF-1 α used as the target nucleotide is hybridized to the bases of the mutant-free wild type probes.

As shown in FIG. 2, a similar result as in FIG. 1 was observed for the immobilized spots of the wild type probes (i.e., SEQ ID Nos. 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, and 33). However, the immobilized spot of the probe of SEQ ID No. 32, which is one of the mutant probes, showed a strong fluorescent intensity, unlike the result of FIG. 1. The insertion mutation of nucleotide A immediately after the 5613th nucleotide of the exon 9 region of the HNF-1 α gene can be easily identified.

Example 6: Manufacture of Biochip using Matrix Directly formed on Substrate

According to the present invention, the matrix can be directly formed on a substrate as well as can be manufactured in a container separate from the substrate.

In a carbonate buffer solution (0.25 mM, pH 9.5) an oligonucleotide probe (5'-tgttctctgtcttg-3': SEQ ID No. 35), the star-like polyethylene derivative having the epoxy group prepared in Example 1, and the diamine cross-linking agent prepared in Example 2 were mixed in a ratio of 1:8:8. The concentration of the oligonucleotide was adjusted not to exceed 400 μ M. Next, the mixture solution was mixed with an equal volume of DMSO and applied by spotting to the glass surface which had been treated to expose amide groups. After the spotting, the biochip was put in an oven at a temperature of 60°C and a humidity of 40% and incubated for 1 hour, followed by a post-processing with succinic anhydride. The post-processing is to prevent a non-specific reaction of an unreacted amino group on the glass surface, epoxy group of a star-like PEG derivative having an epoxy group and amino group of a probe.

On the resultant biochip, a hybridization reaction between the probe and a target nucleotide was performed. The result of scanning the chip surface is shown in FIG. 3. Here, the target nucleotide used was an artificial oligonucleotide complementary to the probe. In FIG. 3, "C" is for the biochip manufactured in this example, "B" is for the biochip manufactured in Example 4, and "A" is for a biochip manufactured by spotting only a DNA solution on a glass substrate. As is apparent from FIG. 3, the biochip "C" showed a fluorescent intensity 5-7 times greater than the biochip "B", and the biochip "A" showed a fluorescent intensity 2-3 times greater than the biochip "B".

As described above, according to the present invention, a 3D biochip having a structure where it spatially protrudes from its surface can be manufactured, and chip sensitivity is greatly increased. In addition, the biochip according to the present invention can be conveniently and efficiently manufactured using an aqueous solution at low costs.

What is claimed is:

1. A method for manufacturing a hydrogel biochip, comprising:

5 Mixing a star-like polyethylene glycol derivative having an epoxy group at its terminal, a hydrophilic polymeric cross-linking agent and a probe in a aqueous solution to form a mixture solution; and

Applying the mixture solution on a substrate to form a hydrogel such that the probe is immobilized to the substrate.

10 2. The method of claim 1, wherein the mixing comprises mixing a star-like polyethylene glycol derivative having the epoxy group at its terminal and the hydrophilic polymeric cross-linking agent to form a matrix solution; and adding a probe to the matrix to form a mixture solution containing a matrix solution and a probe solution.

15 3. The method of claim 1, wherein the applying the mixture solution on a substrate is performed at a temperature of about 40-70°C and a humidity of about 60-30%.

20 4. The method of any one of claims 1 through 4, wherein the hydrophilic polymeric cross-linking agent has an average molecular weight of about 60-100,000 and is a star-like polyethylene glycol derivative having a hydroxy group, an amino group, or a thiol group.

25 5. The method of any one of claims 1 through 4, wherein the probe is a deoxyribonucleic acid (DNA), a ribonucleic acid (RNA), a peptide nucleic acid (PNA), a protein, or an oligopeptide.

30 6. The method of claim 1 or 4, further comprising treating a surface of the substrate to have an amine group.

7. The method of any one of claims 1 through 4, wherein the substrate is formed of a material selected from the group consisting of glass, quartz, silicon, plastic, polypropylene, polycarbonate, and activated acrylamide.

5 8. A hydrogel biochip manufactured by the method according to one of claims 1 through 4.

9. An assay method for detecting a binding between a probe and a target substance, comprising:

10 Applying a sample containing a target substance to be bound to a probe, to the hydrogel biochip manufactured by the method according to one of claims 1 through 4; and

Detecting the target substance specifically bound to the probe.

15 10. The assay method of claim 10, wherein the target substance is a fluorescence-labeled biomolecule.

Fig. 1




Fig. 2





Fig. 3



SEQUENCE LISTING

- <110> SAMSUNG ELECTRONICS CO., LTD.
- <120> A method of preparing a hydrogel biochip by using PEG derivatives
- <160> 35
- <170> KopatentIn 1.71
- <210> 1
- <211> 15
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> A probe complementary to promoter region of HNF-1a gene, in which the central 't' base pairs with the 432nd base of the wild type promoter.
- <400> 1
tgaactttgg acttc 15
- <210> 2
- <211> 15
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> A probe complementary to promoter region of HNF-1a gene of which the 432nd base has a point mutation(A-C).
- <400> 2
tgaacttggg acttc 15
- <210> 3
- <211> 15
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> A probe complementary to promoter region of HNF-1a gene, in which the central 'g' base pairs with the 592nd base of the wild type promoter.
- <400> 3
gttttggggg ggcag 15
- <210> 4

<211> 15
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> A probe complementary to promoter region of HNF-1a gene of which the 592nd base has a point mutation(C-G).

<400> 4
 gttttggcgg ggcag

15

<210> 5
 <211> 15
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> A probe complementary to exon 1 region of HNF-1a gene, in which the central 'g' base pairs with the 733rd base of the wild type exon 1.

<400> 5
 tgcagctggc tcagt

15

<210> 6
 <211> 15
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> A probe complementary to exon 1 region of HNF-1a gene of which the 733rd base has a point mutation(C-T).

<400> 6
 tgcagctagc tcagt

15

<210> 7
 <211> 15
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> A probe complementary to exon 1 region of HNF-1a gene, in which the central 'g' base pairs with the 806th base of the wild type exon 1.

<400> 7
 gcactgggtg agccg

15

<210> 8
 <211> 15
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> A probe complementary to exon 1 region of HNF-1a gene of which the 806th base has a point mutation(C-T).

<400> 8
 gcactggatg agccg

15

<210> 9
 <211> 15
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> A probe complementary to exon 1 region of HNF-1a gene, in which the central 'g' base pairs with the 856th base of the wild type exon 1.

<400> 9
 caagggggag tcctg

15

<210> 10
 <211> 15
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> A probe complementary to exon 1 region of HNF-1a gene of which the 856th base has a point mutation(C-T).

<400> 10
 caaggggaag tcctg

15

<210> 11
 <211> 15
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> A probe complementary to exon 1 region of HNF-1a gene, in which the central 'g' base pairs with the 875th base of the wild type exon 1.

<400> 11

cggtcgaggg gagct

15

<210> 12
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> A probe complementary to exon 1 region of HNF-1a gene of which the 875th-879th bases are deleted.

<400> 12
ggcggtcgag ctggc

15

<210> 13
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> A probe complementary to exon 2 region of HNF-1a gene, in which the central 't' base pairs with the 1778th base of the wild type exon 2.

<400> 13
accatcttcg ccaca

15

<210> 14
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> A probe complementary to exon 2 region of HNF-1a gene of which the 1778th base has a point mutation(A-G).

<400> 14
accatctccg ccaca

15

<210> 15
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> A probe complementary to exon 2 region of HNF-1a gene, in which the central 't' base pairs with the 1812nd base of the wild type exon 2.

<400> 15
cacaacatcc cacag 15

<210> 16
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> A probe complementary to exon 2 region of HNF-1a gene of which the 1812nd base has a point mutation(A-T).

<400> 16
cacaacaacc cacag 15

<210> 17
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> A probe complementary to exon 2 region of HNF-1a gene, in which the central 'g' base pairs with the 1910th base of the wild type exon 2.

<400> 17
gcgggccgcc ctgta 15

<210> 18
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> A probe complementary to exon 2 region of HNF-1a gene of which the 1910th base has a point mutation(C-T).

<400> 18
gcggggccacc ctgta 15

<210> 19
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> A probe complementary to exon 2 region of HNF-1a gene, in which the central 'g' base pairs with the 1940th base of the wild type

exon 2.

<400> 19
acctctcgct gcttg

15

<210> 20
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> A probe complementary to exon 2 region of HNF-1a gene of which
the 1940th base has a point mutation(C-T).

<400> 20
acctctcact gcttg

15

<210> 21
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> A probe complementary to exon 3 region of HNF-1a gene, in which
the central 'g' base pairs with the 2659th base of the wild type
exon 3.

<400> 21
aaggggcgga ggaac

15

<210> 22
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> A probe complementary to exon 3 region of HNF-1a gene of which
the 2659th base has a point mutation(C-T).

<400> 22
aaggggcaga ggaac

15

<210> 23
<211> 15
<212> DNA
<213> Artificial Sequence

<220>

<223> A probe complementary to exon 3 region of HNF-1a gene, in which the central 'c' base pairs with the 2667th base of the wild type exon 3.

<400> 23
gaggaaccgt tcaa

15

<210> 24
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> A probe complementary to exon 3 region of HNF-1a gene of which the 2667th base has a point mutation(G-A).

<400> 24
gaggaactgt tcaa

15

<210> 25
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> A probe complementary to exon 4 region of HNF-1a gene, in which the central 'g' base pairs with the 3297th base of the wild type exon 4.

<400> 25
cacctccgtg acgag

15

<210> 26
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> A probe complementary to exon 4 region of HNF-1a gene of which the 3297th base has a point mutation(C-T).

<400> 26
cacctccatg acgag

15

<210> 27
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> A probe complementary to exon 4 region of HNF-1a gene, in which the central 'g' base pairs with the 3305th base of the wild type exon 4.

<400> 27
tagacacgca cctcc 15

<210> 28
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> A probe complementary to exon 4 region of HNF-1a gene of which the 3305th base has a point mutation(C-T).

<400> 28
tagacacaca cctcc 15

<210> 29
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> A probe complementary to exon 4 region of HNF-1a gene, in which the central 'c' base pairs with the 3332nd base of the wild type exon 4.

<400> 29
caaccggcgc aaaga 15

<210> 30
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> A probe complementary to exon 4 region of HNF-1a gene of which the 3332nd base has a point mutation(G-A).

<400> 30
caaccggtgc aaaga 15

<210> 31
<211> 15

<212> DNA
<213> Artificial Sequence

<220>

<223> A probe complementary to exon 9 region of HNF-1a gene, in which the central 't' base pairs with the 5613rd of the wild type exon 9.

<400> 31
cctgagatgc cggcg

15

<210> 32
<211> 15
<212> DNA
<213> Artificial Sequence

<220>

<223> A probe complementary to exon 9 region of HNF-1a gene in which 'a' base is inserted after the 5613rd base of exon 9.

<400> 32
cctgagattg ccggc

15

<210> 33
<211> 15
<212> DNA
<213> Artificial Sequence

<220>

<223> A probe complementary to exon 9 region of HNF-1a gene, in which the central 'g' base pairs with the 5688th base of the wild type exon 9.

<400> 33
tggcgctgag ccggt

15

<210> 34
<211> 15
<212> DNA
<213> Artificial Sequence

<220>

<223> A probe complementary to exon 9 region of HNF-1a gene in which 'tc' bases are inserted after the 5688th base of the exon 9.

<400> 34
tggcgctgag agccg

15

<210> 35
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> a synthetic oligonucleotide probe

<400> 35
tgttctcttg tcttg

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR02/01645

A. CLASSIFICATION OF SUBJECT MATTER**IPC7 C12Q 1/68**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7 C12Q 1/68

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA, Delphion, "biochip", "microarray", "polyethylene glycol", "epoxy", "hydrogel"

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01/36683 A2 (Appolo Biotech. Inc.) 25 May 2001. See the whole document.	1-10
A	WO 00/65097 A1 (Biocept Inc.) 02 Nov. 2000. See the whole document.	1-10
A	WO 00/02899 A1 (Biocept Inc.) 20 Jan. 2000. See the whole document.	1-10
A	JP 11172205 A2 (Sumitomo Bakelite Co., Ltd.) 29 Jun. 1999. See abstract.	1-10
A	Giordano, B.B. et al., Electrophoresis, 22(2), 334-40, 2001. See abstract.	1-10
A	US 20010031504 A1 (LG Electronics Inc.) 18 Oct. 2001. See the whole document.	1-10

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

24 DECEMBER 2002 (24.12.2002)

Date of mailing of the international search report

26 DECEMBER 2002 (26.12.2002)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office
920 Dunsan-dong, Seo-gu, Daejeon 302-701,
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

LEE, Cheo Young

Telephone No. 82-42-481-5594



Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT


Information on patent family members

International application No.

PCT/KR02/01645

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 01/36683 A2	25 May 2001	AU 200117719 A5	30 May 2001
WO 00/65097 A1	02 Nov. 2000	AU 0046690 A5 EP 1173620 A1 US 6,174,683 B1	10 Nov. 2000 23 Jan. 2002 16 Jan. 2001
WO 00/02899 A1	20 Jan. 2000	AU 4965499 A1 EP 1095054 A1 JP 2002520008 T2 US 6,433,134 B1	01 Feb. 2000 02 May 2001 09 Jul. 2002 13 Aug. 2002
JP 11172205 A2	29 Jun. 1999	none	
US 20010031504 A1	18 Oct. 2001	KR 2001-0096721 A	08 Nov. 2001

100



(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
13 March 2003 (13.03.2003)

PCT

(10) International Publication Number
WO 2003/020978 A1

- (51) International Patent Classification⁷: **C12Q 1/68**
- (21) International Application Number:
PCT/KR2002/001645
- (22) International Filing Date: 30 August 2002 (30.08.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
2001/53687 1 September 2001 (01.09.2001) KR
2002/48128 14 August 2002 (14.08.2002) KR
- (71) Applicant: **SAMSUNG ELECTRONICS CO., LTD.**
[KR/KR]; 416 Maetan-dong, Paldal-gu, Suwon-city,
442-373 Kyungki-do (KR).
- (72) Inventors: **HUH, Nam**; 5-1101 Mujigae Apt.,
1335, Seocho-dong, Seocho-gu, 137-070 Seoul (KR). **SONG, Mi-Jung**; 111-1205 Sejong Apt., 462-4, Jeon-
min-dong, Yuseong-gu, 305-390 Daejeon (KR). **PARK, Jong-Myeon**; 101-807 Sejong Apt., 462-4, Jeonmin-dong,
Yuseong-gu, 305-390 Daejeon (KR). **PARK, Ga-Young**;
c/o Samsung Advanced Institute of Technology, San
14-1, Nongseo-ri, Kiheung-eub, Yongin-si, 449-712
Gyeonggi-do (KR).
- (74) Agent: **LEE, Young-Pil**; The Cheonghwa Building,
1571-18, Seocho-dong, Seocho-gu, 137-874 Seoul (KR).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN,
YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
— with amended claims
- Date of publication of the amended claims:** 8 April 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHOD FOR MANUFACTURING HYDROGEL BIOCHIP BY USING STAR-LIKE POLYETHYLENE GLYCOL DERIVATIVE HAVING EPOXY GROUP



(57) Abstract: A method for manufacturing a biochip and a biochip manufactured by the method are provided. In the biochip manufacturing method, a star-like polyethylene glycol derivative having an epoxy group at its terminal is reacted with a low molecular weight hydrophilic polymer to form a matrix, and a probe is covalently bound to the matrix and immobilized on a solid substrate. The biochip has a 3-dimensional structure where it spatially protrudes from its surface and improved chip sensitivity. In addition, the biochip can be conveniently and efficiently manufactured using an aqueous solution at low costs.

WO 2003/020978 A1

AMENDED CLAIMS

[received by the International Bureau on 24 February 2003 (24.02.03);
Original claim 10 replaced by amended claim 10; remaining claims unchanged
(1 page)]

7. The method of any one of claims 1 through 4, wherein the substrate is formed of a material selected from the group consisting of glass, quartz, silicon, plastic, polypropylene, polycarbonate, and activated acrylamide.

5 8. A hydrogel biochip manufactured by the method according to one of claims 1 through 4.

9. An assay method for detecting a binding between a probe and a target substance, comprising:

10 Applying a sample containing a target substance to be bound to a probe, to the hydrogel biochip manufactured by the method according to one of claims 1 through 4; and

Detecting the target substance specifically bound to the probe.

15 10. The assay method of claim 9, wherein the target substance is a fluorescence-labeled biomolecule.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)